Zarrabian Saiid 4
4 · DelMar Pharmaceuticals, Inc. · Filed Jun 30, 2020
Insider Transaction Report
Form 4
Zarrabian Saiid
DirectorInterim CEO
Transactions
- Award
Options (Right to Buy)
2020-06-26+241,438→ 457,650 totalExercise: $0.61Exp: 2029-09-05→ Common Stock (241,438 underlying)
Footnotes (2)
- [F1]On September 5, 2019, the reporting person received options to purchase 241,438 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020.
- [F2]1/6th of the options vested on March 5, 2020 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 5, 2020.